Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: Preliminary observations

American Journal of Roentgenology

Volumn 196, Issue 3, 2011, Pages 545-552

  De Campos, Rafael O P ^a   Heredia, Vasco ^a   Ramalho, Miguel ^a   De Toni, Marcos S ^a   Lugo Somolinos, Aida ^a   Fuller III, Edwin R ^a   Semelka, Richard C ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

Gadobenate dimeglumine; Gadolinium; MRI; Nephrogenic systemic fibrosis; Quarter dose

Indexed keywords

GADOBENATE DIMEGLUMINE;

ADULT; AORTA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; HUMAN; IMAGE ENHANCEMENT; KIDNEY CORTEX; LIVER; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN; PANCREAS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEASIBILITY STUDIES; FEMALE; HUMANS; KIDNEY DISEASES; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; ORGANOMETALLIC COMPOUNDS; PREGNANCY; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 79952271584     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.4500     Document Type: Article

References (34)

1. Martin DR, Semelka RC. Magnetic resonance imaging of the liver: review of techniques and approach to common diseases. Semin Ultrasound CT MR 2005; 26:116-131 (Pubitemid 40780949)
2. Semelka RC, Martin DR, Balci NC. Magnetic resonance imaging of the liver: how I do it. J Gastroenterol Hepatol 2006; 21:632-637
3. Altun E, Semelka RC, Cakit C. Nephrogenic systemic fibrosis and management of high-risk patients. Acad Radiol 2009; 16:897-905
4. Hunt CH, Hartman RP, Hesley GK. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR 2009; 193:1124-1127
5. Penfield JG, Reilly RF Jr. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol 2007; 3:654-668 (Pubitemid 350146964)
6. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1104-1108
7. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008; 248:799-806
8. Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER 3rd, Semelka RC. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy - report from two U.S. universities. Radiology 2009; 253:689-696
9. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243:148-157 (Pubitemid 46579705)
10. Rofsky NM, Sherry AD, Lenkinski RE. Nephrogenic systemic fibrosis: a chemical perspective. Radiology 2008; 247:608-612
11. Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment - report of 33 cases. Radiology 2009; 250:371-377
12. Abujudeh HH, Kaewlai R, Kagan A, et al. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology 2009; 253:81-89
13. Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN. Nephrogenic systemic fibrosis and its impact on abdominal imaging. Radio-Graphics 2009; 29:1565-1574
14. Thomsen HS. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States. Radiol Clin North Am 2009; 47: 871-875, vii
15. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR 2007; 188:1447-1474
16. Juluru K, Vogel-Claussen J, Macura KJ, Kamel IR, Steever A, Bluemke DA. MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety. RadioGraphics 2009; 29:9-22
17. Martin DR, Krishnamoorthy SK, Kalb B, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010; 31: 440-446
18. Abujudeh HH, Rolls H, Kaewlai R, et al. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging 2009; 30:1335-1340
19. Bryant BJ 2nd, Im K, Broome DR. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Clin Radiol 2009; 64:706-713
20. Lin SP, Brown JJ. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging 2007; 25:884-899
21. Balci NC, Semelka RC. Contrast agents for MR imaging of the liver. Radiol Clin North Am 2005; 43:887-898, viii
22. Runge VM, Kenney CM. Phase II double-blind, dose-ranging clinical evaluation of gadobenate dimeglumine in focal liver lesions: with analysis of liver and kidney signal change on early and delayed imaging. J Magn Reson Imaging 2000; 11: 655-664 (Pubitemid 30350309)
23. Schneider G, Maas R, Schultze Kool L, et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 2003; 38:85-94 (Pubitemid 36125892)
24. Kirchin MA, Spinazzi A. Low-dose gadobenate dimeglumine-enhanced MRI in the detection and characterization of focal liver lesions. Acad Radiol 2002; 9[suppl 1]:S121-S126 (Pubitemid 34441461)
25. Schneider G, Altmeyer K, Kirchin MA, et al. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging. Invest Radiol 2007; 42:105-115 (Pubitemid 46104891)
26. Nural MS, Gokce E, Danaci M, Bayrak IK, Diren HB. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/ kg dose. Eur J Radiol 2008; 66:65-74 (Pubitemid 351434515)
27. Ramalho M, Heredia V, Tsurusaki M, Altun E, Semelka RC. Quantitative and qualitative comparison of 1.5 and 3.0 Tesla MRI in patients with chronic liver diseases. J Magn Reson Imaging 2009; 29:869-879
28. Erturk SM, Alberich-Bayarri A, Herrmann KA, Marti-Bonmati L, Ros PR. Use of 3.0-T MR imaging for evaluation of the abdomen. Radio-Graphics 2009; 29:1547-1563
29. Goncalves Neto JA, Altun E, Elazzazi M, Vaidean GD, Chaney M, Semelka RC. Enhancement of abdominal organs on hepatic arterial phase: quantitative comparison between 1.5- and 3.0-T magnetic resonance imaging. Magn Reson Imaging 2010; 28:47-55
30. Lowry R. VassarStats: Website for statistical computation.faculty.vassar. edu/lowry/VassarStats. html. Accessed June 2010
31. Kroencke TJ, Wasser MN, Pattynama PM, et al. Gadobenate dimeglumine-enhanced MR angiography of the abdominal aorta and renal arteries. AJR 2002; 179:1573-1582 (Pubitemid 35386663)
32. Schneider G, Ballarati C, Grazioli L, et al. Gadobenate dimeglumine-enhanced MR angiography: diagnostic performance of four doses for detection and grading of carotid, renal, and aorto-iliac stenoses compared to digital subtraction angiography. J Magn Reson Imaging 2007; 26:1020-1032 (Pubitemid 47548164)
33. Wikstrom J, Wasser MN, Pattynama PM, et al. Gadobenate dimeglumine-enhanced magnetic resonance angiography of the pelvic arteries. Invest Radiol 2003; 38:504-515 (Pubitemid 36875547)
34. Abdel-Kader K, Patel PR, Kallen AJ, Sinkowitz-Cochran RL, Bolton WK, Unruh ML. Nephrogenic systemic fibrosis: a survey of nephrologists' perceptions and practices. Clin J Am Soc Nephrol 2010; 5:964-971